The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-2159
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2006
Authors
Publisher
American Association for Cancer Research (AACR)